Expediting Patient Identification of LGI1-IgG Autoimmune Encephalitis for Enrollment into Phase 2 Study

Overview

About this study

The purpose of this study is to expedite patient identification of LGI1-IgG autoimmune encephalitis patients for enrollment in the UCB sponsored phase 2 study evaluating the effectiveness and safety of rozanolixizumab.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

LGI1 IgG+ patients 18-89 years of age.

Exclusion Critieria:

< 18 years of age.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/11/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Divyanshu Dubey, M.B.B.S.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Divyanshu Dubey, M.B.B.S.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials